Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Contraception. 2020 Feb 26;101(6):420–426. doi: 10.1016/j.contraception.2020.02.006

Table 4.

Risk for bone disease with 3-month DMPA injectable contraceptive use during years 2012–2016 among women with Cystic Fibrosis, ages 18–49 years in the CF Foundation Patient Registry who completed contraceptive surveys.

Osteopenia (N = 62)
 Osteoporosis (N = 14)
 Osteopenia or Osteoporosis (N = 66)
N (%) Adjusted OR* (95% CI) N (%) Adjusted OR* (95% CI) N (%) Adjusted OR* (95% CI)
Never used DMPA (N = 57)** 23 (40.4) REF 4 (7.0) REF 23 (40.4) REF
Used DMPA (N = 11) 4 (36.4) 0.79 (0.20–3.11) 3 (27.3) 5.36 (1.00–29.12) 5 (45.5) 1.17 (0.31–4.41)
*

Adjusted for binary average BMI (<19, ≥19) from 2012 to 2016.

**

Respondents who used LARC or CHC (N = 81) were removed from the 138 who never used DMPA from 2012 to 2016.